stoxline Quote Chart Rank Option Currency Glossary
  
Hepion Pharmaceuticals, Inc. (HEPA)
0.318  -0.074 (-18.79%)    05-12 16:00
Open: 0.385
High: 0.414
Volume: 2,478,370
  
Pre. Close: 0.3916
Low: 0.3148
Market Cap: 3(M)
Technical analysis
2025-05-12 4:48:44 PM
Short term     
Mid term     
Targets 6-month :  0.65 1-year :  0.87
Resists First :  0.55 Second :  0.74
Pivot price 0.31
Supports First :  0.25 Second :  0.2
MAs MA(5) :  0.36 MA(20) :  0.31
MA(100) :  8.43 MA(250) :  27.81
MACD MACD :  -0.4 Signal :  -0.5
%K %D K(14,3) :  49.1 D(3) :  53.3
RSI RSI(14): 30.5
52-week High :  68 Low :  0.16
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ HEPA ] has closed below upper band by 47.4%. Bollinger Bands are 98.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 34 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.41 - 0.42 0.42 - 0.42
Low: 0.31 - 0.31 0.31 - 0.31
Close: 0.31 - 0.32 0.32 - 0.32
Company Description

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Headline News

Mon, 12 May 2025
Hepion Pharmaceuticals (HEPA) to be Delisted from Nasdaq | HEPA Stock News - GuruFocus

Mon, 12 May 2025
Hepion Pharmaceuticals (HEPA) Faces Nasdaq Delisting, Moves to O - GuruFocus

Mon, 12 May 2025
Hepion Pharmaceuticals to be delisted from Nasdaq - Investing.com

Mon, 12 May 2025
Hepion Pharmaceuticals Announces Receipt of Delisting Notificati - GuruFocus

Mon, 12 May 2025
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq - GlobeNewswire

Mon, 12 May 2025
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq - Stock Titan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 11 (M)
Held by Insiders 1.098e+007 (%)
Held by Institutions 0.1 (%)
Shares Short 200 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -5
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -122.8 %
Return on Equity (ttm) -487.1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.01684e+007
Qtrly Earnings Growth 367.5 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -18 (M)
Stock Valuations
PE Ratio -0.07
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -0.03
Stock Dividends
Dividend 0
Forward Dividend 448180
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android